{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:30:36Z","timestamp":1788870636722,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Kitasato Institute Hospital, Tokyo, Japan"},{"name":"Meiji Pharmaceutical University, Tokyo, Japan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1111\/jcpt.12127","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T02:29:47Z","timestamp":1389320987000},"page":"181-185","source":"Crossref","is-referenced-by-count":4,"title":["Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis"],"prefix":"10.1155","volume":"39","author":[{"given":"S.","family":"Shibata","sequence":"first","affiliation":[{"name":"Department of Pharmacy; Kitasato Institute Hospital; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics; Meiji Pharmaceutical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Keio University School of Medicine; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Keio University School of Medicine; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kubo","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy; Iwaki Meisei University; Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy; Center for Clinical Pharmacy and Sciences; School of Pharmacy; Kitasato University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Saitama City Hospital; Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Inamoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Kitasato Institute Hospital; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Machida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Misato Central General Hospital; Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Atsuda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Kitasato Institute Hospital; Tokyo Japan"},{"name":"Department of Clinical Pharmacy; Center for Clinical Pharmacy and Sciences; School of Pharmacy; Kitasato University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Echizen","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy; Meiji Pharmaceutical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"10.1111\/jcpt.12127-BIB0001|jcpt12127-cit-0001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/09546630701243418","article-title":"Review of antifungal therapy and the severity index assessing onychomycosis: Part I","volume":"19","author":"Baran","year":"2008","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/jcpt.12127-BIB0002|jcpt12127-cit-0002","first-page":"851","article-title":"The guideline for the treatment of dermatophyte infection","volume":"19","author":"Watanabe","year":"2009","journal-title":"Jpn J Dermatol"},{"key":"10.1111\/jcpt.12127-BIB0003|jcpt12127-cit-0003","first-page":"858","article-title":"A multi-center study for the efficacy and patient acceptability for the oral antifungal treatment of onychomycosis: comparison between itraconazole pulse therapy and continuous terbinafine therapy","volume":"61","author":"Watanabe","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1111\/jcpt.12127-BIB0004|jcpt12127-cit-0004","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.1994.184","article-title":"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole","volume":"56","author":"Varhe","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12127-BIB0005|jcpt12127-cit-0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12127-BIB0006|jcpt12127-cit-0006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1067\/mcp.2002.125559","article-title":"Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by change in plasma lansoprazole levels and partial cortisol clearance to 6\u03b2-hydroxycortisol","volume":"72","author":"Ushiama","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12127-BIB0007|jcpt12127-cit-0007","first-page":"118","article-title":"The relevance clinical outcome versus drug and active metabolite concentrations in nail in patient with tinea unguium during itraconazole pulse therapy","volume":"27","author":"Shibata","year":"2010","journal-title":"Jpn J Ther Drug Monit"},{"key":"10.1111\/jcpt.12127-BIB0008|jcpt12127-cit-0008","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002130050715","article-title":"Effect of itraconazole on the single dose pharmacokinetics and pharmacodynamics of alprazolam","volume":"139","author":"Yasui","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1111\/jcpt.12127-BIB0009|jcpt12127-cit-0009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12127-BIB0010|jcpt12127-cit-0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12127-BIB0011|jcpt12127-cit-0011","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12127-BIB0012|jcpt12127-cit-0012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12127-BIB0013|jcpt12127-cit-0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.1989.tb03516.x","article-title":"The increase in urinary excretion of 6\u03b2-hydroxycortisol as marker of human hepatic cytochrome P450III induction","volume":"28","author":"Ged","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12127-BIB0014|jcpt12127-cit-0014","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0009-9236(99)70029-9","article-title":"Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A","volume":"66","author":"Kinirons","year":"1999","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12127","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12127\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:05:13Z","timestamp":1671800713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12127","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,10]]}}}